Investigational Drug Information for Bifeprunox
What is the drug development status for Bifeprunox?
Bifeprunox is an investigational drug.
There have been 20 clinical trials for Bifeprunox.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2005.
The most common disease conditions in clinical trials are Schizophrenia, Psychotic Disorders, and Depression. The leading clinical trial sponsors are Solvay Pharmaceuticals, Wyeth is now a wholly owned subsidiary of Pfizer, and H. Lundbeck A/S.
Summary for Bifeprunox
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,695 |
| WIPO Patent Applications | 660 |
| Japanese Patent Applications | 212 |
| Clinical Trial Progress | Phase 3 (2005-05-01) |
| Vendors | 26 |
Recent Clinical Trials for Bifeprunox
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of Bifeprunox in Patients With Schizophrenia | H. Lundbeck A/S | Phase 3 |
| Efficacy of Bifeprunox in Patients With Schizophrenia | H. Lundbeck A/S | Phase 3 |
| Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
Clinical Trial Summary for Bifeprunox
Top disease conditions for Bifeprunox
Top clinical trial sponsors for Bifeprunox
US Patents for Bifeprunox
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Bifeprunox Development Update, Patent Status, FDA History, and Market Projection
Bifeprunox is a discontinued investigational antipsychotic that did not obtain FDA approval. Development centered on schizophrenia, with later interest in bipolar disorder and metabolic advantages relative to some atypical antipsychotics. The program failed to establish sufficient efficacy for regulatory approval, and no active commercial development program is publicly evident.
The commercial outlook is therefore effectively zero as a standalone product. Bifeprunox has no FDA-approved reference product, no Orange Book exclusivity, no biosimilar pathway, and no credible near-term launch scenario. Any future development would require a new sponsor, renewed clinical development, and a regulatory strategy capable of addressing the prior efficacy concerns.
What is bifeprunox and what was it designed to treat?
Bifeprunox, also known as DU-127090 and SLV313 in development materials, is a small-molecule dopamine and serotonin receptor modulator. The drug was developed primarily by H. Lundbeck A/S and Solvay Pharmaceuticals.
Its pharmacology was intended to differentiate it from conventional dopamine D2 antagonists:
| Characteristic | Bifeprunox |
|---|---|
| Drug class | Investigational atypical antipsychotic |
| Principal mechanism | Dopamine D2 partial agonism with serotonergic activity |
| Primary target indication | Schizophrenia |
| Other development interests | Bipolar disorder and related psychiatric indications |
| Route | Oral |
| Regulatory status | Not approved |
| Commercial status | Development discontinued |
| Reference product | None |
| Orange Book listing | None |
Bifeprunox was positioned as a potentially metabolically favorable antipsychotic. The development rationale reflected growing concern about weight gain, glucose abnormalities, dyslipidemia, and other adverse effects associated with several second-generation antipsychotics.
The mechanism was conceptually related to the partial dopamine agonism used by aripiprazole, but bifeprunox was a distinct chemical entity and was not a generic or follow-on version of aripiprazole.
What was the clinical development history of bifeprunox?
Bifeprunox progressed into mid- and late-stage clinical development for schizophrenia. Public development materials described randomized trials evaluating efficacy, safety, tolerability, and metabolic effects.
Key development milestones
| Period | Development event |
|---|---|
| Early 2000s | Bifeprunox entered clinical development as a novel antipsychotic |
| Mid-2000s | Phase II and Phase III schizophrenia studies were conducted |
| 2006-2007 | U.S. regulatory submission activity was reported |
| 2007 | The FDA did not approve the application and requested additional evidence |
| 2008-2009 | Further development and regulatory activity continued in a limited form |
| 2009-2010 | The program was effectively discontinued |
| Present | No approved product or active late-stage program |
The central problem was efficacy. Although the compound showed antipsychotic activity in clinical testing, the overall evidence was not sufficient for FDA approval. Safety and metabolic findings could not compensate for an efficacy package that regulators considered inadequate.
The public record does not support a commercial launch in the United States, Europe, or other major pharmaceutical markets.
Why did the FDA reject or fail to approve bifeprunox?
The FDA’s principal concern was inadequate evidence of efficacy rather than a single dominant toxicity finding.
Regulatory approval for schizophrenia requires reproducible symptom improvement supported by controlled trials and an acceptable benefit-risk balance. Bifeprunox did not meet that standard in the submitted package. Reports from the period indicate that the FDA sought additional clinical evidence after reviewing the application.
The program’s regulatory challenges included:
- Inconsistent efficacy across clinical studies.
- Difficulty demonstrating a sufficient treatment effect against placebo.
- A competitive market dominated by approved antipsychotics with established efficacy and commercial distribution.
- The need to demonstrate a clinically meaningful advantage over existing therapies.
- Limited value from metabolic differentiation when efficacy remained uncertain.
The FDA’s action was not equivalent to a market withdrawal because bifeprunox had never been approved. It was a failure to secure approval for the submitted development program.
What is the current development status of bifeprunox?
Bifeprunox is discontinued from a commercial development perspective.
There is no public evidence of:
- An approved New Drug Application.
- An active U.S. marketing application.
- An active Phase III registration program.
- A current originator-sponsored clinical development plan.
- A commercial product supply chain.
- A post-marketing safety database.
- A current licensing or co-development transaction.
- A planned resubmission to the FDA.
The compound may remain relevant as a historical pharmacology asset or as a research reference. That status is different from an active drug-development program.
ClinicalTrials.gov and historical sponsor disclosures provide the main public evidence base for the program’s development history. The absence of current sponsor activity, regulatory progress, or commercial investment supports a discontinued classification rather than a delayed launch classification (ClinicalTrials.gov, n.d.; H. Lundbeck A/S, 2007-2010).
What patents protect bifeprunox?
Bifeprunox was protected historically through compound, pharmaceutical-composition, and potentially therapeutic-use patent filings. The available public record does not support treating those historical rights as a current commercial barrier.
Because the drug was never approved, its historical patent estate did not mature into a conventional branded-product exclusivity position under the Hatch-Waxman framework.
Patent categories associated with the program
| Patent category | Business relevance |
|---|---|
| Composition-of-matter patents | Historically the most important rights for the active molecule |
| Salt, polymorph, or formulation patents | Potential secondary protection, subject to claim scope and validity |
| Pharmaceutical-composition patents | Covered dosage forms or drug-containing compositions |
| Method-of-use patents | Could cover treatment of schizophrenia or other psychiatric conditions |
| Process patents | Could protect manufacturing routes or intermediates |
| International filings | Could create country-specific rights with different expiration dates |
The practical strength of the estate is low today for four reasons:
- The program was discontinued.
- The molecule has no approved reference product.
- Any early priority filings would have been subject to ordinary patent-term attrition.
- No commercial product currently depends on enforcing the rights.
A definitive patent-by-patent expiration analysis would require confirmation of the relevant priority families, granted claims, terminal disclaimers, patent-term adjustments, national-stage prosecution, and abandonment status. Public business relevance is limited even where historical patents remain unexpired because no approved product is being sold.
When does bifeprunox lose exclusivity?
Bifeprunox has no current FDA regulatory exclusivity because it was never approved.
The relevant distinction is between patent rights and FDA exclusivity:
| Exclusivity type | Bifeprunox status |
|---|---|
| New chemical entity exclusivity | Never awarded |
| New clinical investigation exclusivity | Never awarded through an approved application |
| Orphan-drug exclusivity | No established U.S. orphan approval |
| Pediatric exclusivity | None |
| Reference-product exclusivity | None |
| Patent-based Orange Book exclusivity | None |
| Biosimilar reference-product exclusivity | Not applicable |
Any historical patent protection would expire independently of FDA exclusivity. Since no approved product exists, a generic applicant cannot file a standard ANDA against bifeprunox as an FDA reference product.
What is the Orange Book status of bifeprunox?
Bifeprunox is not an Orange Book-listed drug.
The FDA Orange Book lists approved drug products and, where applicable, patents and regulatory exclusivities associated with those products. Bifeprunox does not have an approved U.S. product designation and therefore does not have an Orange Book reference listing.
This means there is no current Orange Book patent dispute, no standard Paragraph IV certification against a bifeprunox reference product, and no 30-month stay risk tied to a bifeprunox ANDA.
Which companies are challenging bifeprunox patents?
No active Paragraph IV challenge or major patent litigation involving bifeprunox is publicly established.
The likely reason is commercial, not technical. Generic companies generally challenge patents when an approved, high-value reference product has meaningful sales. Bifeprunox never created that market opportunity.
Paragraph IV and litigation assessment
| Issue | Current assessment |
|---|---|
| Paragraph IV ANDA challenge | No established active challenge |
| Abbreviated New Drug Application | No reference-product pathway |
| Patent litigation | No material current litigation identified |
| Settlement agreement | No significant public settlement identified |
| Inter partes review activity | No material commercial dispute established |
| Biosimilar litigation | Not applicable |
If a sponsor revived bifeprunox through a new approval route, historical patents would need to be reviewed for remaining term and enforceability. That scenario would not automatically restore expired composition-of-matter rights.
What formulations were protected by bifeprunox patents?
Bifeprunox was developed as an oral small-molecule product. Historical patent filings may have covered pharmaceutical compositions, dosage forms, salts, solid-state forms, and manufacturing processes.
There is no marketed formulation whose commercial protection requires current enforcement. The main formulation risks for a future sponsor would involve:
- Oral tablets or capsules.
- Dose-ranging compositions.
- Solid-state or salt forms.
- Stability-enhancing excipient systems.
- Manufacturing processes for the active pharmaceutical ingredient.
- Combination products or adjunctive psychiatric regimens.
Formulation patents would be less valuable than a valid composition-of-matter patent because a future competitor could potentially design around a narrow dosage-form claim. A broad, enforceable molecule claim would provide the strongest protection, but its practical value would depend on remaining term and regulatory revival.
Does bifeprunox face biosimilar risk?
No. Bifeprunox is a synthetic small molecule, not a biologic, and no biosimilar pathway applies.
The relevant competitive risk would be generic competition if a product were approved. Since no reference product exists, there is no current generic launch event, ANDA filing, or automatic substitution pathway.
A future sponsor would need to develop bifeprunox as an innovator product or pursue another regulatory route supported by new clinical evidence. The development burden would be materially higher than a conventional generic filing.
How strong is the bifeprunox patent estate?
The patent estate has low current commercial strength and uncertain residual legal strength.
Strength assessment
| Factor | Assessment |
|---|---|
| Composition-of-matter protection | Historically important; current term must be verified by family |
| Regulatory exclusivity | None |
| Orange Book leverage | None |
| Litigation leverage | Low because there is no approved revenue stream |
| Formulation protection | Potentially relevant but secondary |
| Manufacturing protection | May create know-how barriers but not a substitute for product approval |
| Freedom-to-operate value | Requires jurisdiction-specific review |
| Licensing value | Limited without new clinical investment |
Patent strength is only one part of asset value. For bifeprunox, the greater constraint is clinical and regulatory validation. A buyer would inherit a molecule with prior efficacy concerns, a long development gap, and no established commercial franchise.
What licensing deals involved bifeprunox?
Bifeprunox was associated with a collaboration between Lundbeck and Solvay Pharmaceuticals. The collaboration reflected a conventional originator partnership in which development and commercialization responsibilities were shared or allocated between the parties.
Solvay Pharmaceuticals was later acquired by Abbott Laboratories in 2010. That transaction changed ownership of Solvay’s pharmaceutical assets, but it did not produce a commercial bifeprunox launch.
No current licensing transaction or active commercial partner is publicly associated with bifeprunox. Any historical rights retained by successor companies would need to be assessed against assignment records, termination provisions, and patent-family status.
What generic launch risks exist for bifeprunox?
There is no immediate generic launch risk because there is no approved product.
A future approval could create the following competitive scenarios:
| Scenario | Probability assessment |
|---|---|
| No further development | Highest |
| Academic or investigator-led revival | Low |
| New sponsor conducts a full clinical program | Very low |
| Approval followed by generic entry | Remote and distant |
| Reformulation or repurposing | Low |
The most credible commercial outcome is continued nondevelopment. The program does not present the usual branded-drug exposure to patent expiry because it never reached the market.
What is the market projection for bifeprunox?
The base-case revenue projection is zero.
Bifeprunox has no approved label, no sales, no reimbursement status, no distribution network, and no active launch plan. A conventional peak-sales forecast is therefore not supportable.
Scenario-based commercial projection
| Scenario | Indicative probability | Revenue outlook |
|---|---|---|
| Continued discontinuation | 95% or higher | $0 |
| Academic revival without commercialization | Low | $0 |
| Reacquisition and renewed Phase II development | Very low | No revenue for many years |
| Successful global approval | Remote | Uncertain, dependent on new trials |
| Commercial launch after approval | Remote | Potentially modest relative to established antipsychotics |
A hypothetical relaunch would face severe competition from generic aripiprazole, risperidone, quetiapine, olanzapine, and other established antipsychotics. It would also compete with newer long-acting injectables and branded therapies positioned around efficacy, tolerability, adherence, or treatment-resistant disease.
A revived bifeprunox product would need a clear clinical advantage, such as improved metabolic outcomes without sacrificing efficacy, to justify premium pricing. Historical pharmacologic differentiation alone would not support a large forecast.
How does bifeprunox compare with aripiprazole?
Bifeprunox and aripiprazole share a broad pharmacologic concept involving dopamine partial agonism, but their commercial positions are fundamentally different.
| Factor | Bifeprunox | Aripiprazole |
|---|---|---|
| FDA approval | None | Approved |
| Commercial launch | None | Global commercial product |
| Reference product | None | Abilify and related products |
| Generic competition | Not applicable | Established |
| Clinical database | Incomplete for approval | Extensive |
| Regulatory exclusivity | None | Historical exclusivity and patents |
| Market access | None | Broad |
| Current development value | Speculative | Established product and lifecycle asset |
Aripiprazole’s clinical and commercial validation created substantial value even after generic entry. Bifeprunox did not reach the regulatory threshold required to create comparable asset value.
What patent litigation affects bifeprunox?
No material current patent litigation is publicly associated with bifeprunox.
The absence of litigation is consistent with the program’s status. Patent disputes generally arise when a product has meaningful sales, a near-term generic threat, or a valuable licensing position. Bifeprunox has none of those characteristics today.
Historical patent prosecution and ownership records may still exist in the United States and other jurisdictions, but they do not create current launch exposure without an approved product.
What are the main manufacturing and intellectual-property barriers?
Manufacturing is unlikely to be the primary barrier. Bifeprunox is a small molecule, and a capable pharmaceutical manufacturer could potentially reproduce the active ingredient and oral dosage form if the process were legally available.
The more important barriers are:
- Rebuilding the clinical efficacy package.
- Establishing a current safety database.
- Selecting a viable indication and dose.
- Demonstrating differentiation against generic antipsychotics.
- Confirming freedom to operate in key markets.
- Determining whether historical patents remain enforceable.
- Financing a new registration program.
Manufacturing know-how, impurity control, polymorph selection, and process scale-up could affect development cost. They would not eliminate the need for clinical and regulatory redevelopment.
Key Takeaways
- Bifeprunox is an investigational antipsychotic that was not approved by the FDA.
- The primary development indication was schizophrenia.
- The program’s main failure was inadequate or inconsistent efficacy evidence.
- Lundbeck and Solvay were the principal historical development companies.
- Bifeprunox has no Orange Book listing, FDA exclusivity, or approved reference product.
- No material current Paragraph IV challenge, biosimilar dispute, or patent litigation is established.
- Historical patents may remain relevant for legal analysis, but they have limited commercial value without an approved product.
- The base-case market projection is $0 revenue.
- Any revival would require a new sponsor, substantial clinical investment, and a compelling efficacy or tolerability advantage.
FAQs
Is bifeprunox still being developed for schizophrenia?
No active commercial development program is publicly established. The schizophrenia program was discontinued after the compound failed to secure FDA approval.
Was bifeprunox ever approved in Europe?
No major commercial approval or sustained European launch is established in the public development record.
Is bifeprunox a generic version of Abilify?
No. Bifeprunox is a distinct investigational molecule. Its dopamine partial agonism created a mechanistic comparison with aripiprazole, but it was not aripiprazole or a generic version of Abilify.
Could bifeprunox be repurposed for bipolar disorder?
A future sponsor could study that indication, but prior development history would not eliminate the need for new clinical evidence. No approved bipolar indication exists.
What is the investment value of bifeprunox today?
The asset has limited standalone investment value. Its value would depend on verified surviving patent rights, access to historical clinical data, a credible new sponsor, and evidence that efficacy concerns could be resolved.
References
ClinicalTrials.gov. (n.d.). Clinical studies involving bifeprunox and DU-127090. U.S. National Library of Medicine.
H. Lundbeck A/S. (2007-2010). Annual reports and research-and-development disclosures. H. Lundbeck A/S.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. U.S. Department of Health and Human Services.
U.S. National Library of Medicine. (n.d.). PubChem compound summary for bifeprunox. National Center for Biotechnology Information.
World Health Organization. (n.d.). INN recommended lists and pharmaceutical substance information. World Health Organization.
More… ↓
